Evercore ISI Initiates Coverage on Agilent Technologies (A)

Stock analysts at Evercore ISI started coverage on shares of Agilent Technologies (NYSE:A) in a research report issued on Wednesday. The firm set an “outperform” rating and a $75.00 price target on the medical research company’s stock. Evercore ISI’s price target would suggest a potential upside of 9.01% from the stock’s previous close.

A number of other research firms also recently commented on A. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 price objective on the stock in a report on Tuesday, October 31st. Robert W. Baird reiterated a “buy” rating and issued a $70.00 target price on shares of Agilent Technologies in a research note on Friday, October 20th. Cowen reiterated a “hold” rating and issued a $70.00 target price on shares of Agilent Technologies in a research note on Wednesday, November 22nd. Deutsche Bank set a $75.00 target price on Agilent Technologies and gave the company a “buy” rating in a research note on Tuesday, November 21st. Finally, JPMorgan Chase & Co. increased their target price on Agilent Technologies to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 21st. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Agilent Technologies currently has an average rating of “Buy” and an average price target of $68.78.

Agilent Technologies (NYSE:A) opened at $68.80 on Wednesday. The company has a market capitalization of $22,391.61, a PE ratio of 32.76, a PEG ratio of 2.10 and a beta of 1.28. The company has a quick ratio of 2.85, a current ratio of 3.30 and a debt-to-equity ratio of 0.37. Agilent Technologies has a twelve month low of $46.35 and a twelve month high of $70.93.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 15.30%. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period last year, the business posted $0.59 EPS. equities research analysts anticipate that Agilent Technologies will post 2.58 earnings per share for the current year.

In related news, VP Mark Doak sold 4,154 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $67.00, for a total value of $278,318.00. Following the sale, the vice president now owns 68,270 shares of the company’s stock, valued at approximately $4,574,090. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael R. Mcmullen sold 22,481 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $68.77, for a total value of $1,546,018.37. Following the completion of the sale, the chief executive officer now directly owns 336,637 shares in the company, valued at approximately $23,150,526.49. The disclosure for this sale can be found here. In the last quarter, insiders sold 132,588 shares of company stock valued at $9,186,710.

Several hedge funds and other institutional investors have recently made changes to their positions in A. Neuberger Berman Group LLC lifted its holdings in shares of Agilent Technologies by 360.4% in the 2nd quarter. Neuberger Berman Group LLC now owns 45,303 shares of the medical research company’s stock worth $2,687,000 after purchasing an additional 35,463 shares during the last quarter. Oppenheimer & Co. Inc. raised its stake in Agilent Technologies by 2.3% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 6,973 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 156 shares in the last quarter. Fiduciary Trust Co. bought a new stake in Agilent Technologies during the 2nd quarter valued at $186,000. Old Mutual Global Investors UK Ltd. bought a new stake in Agilent Technologies during the 2nd quarter valued at $7,117,000. Finally, Commonwealth Bank of Australia raised its stake in Agilent Technologies by 275.5% during the 2nd quarter. Commonwealth Bank of Australia now owns 20,899 shares of the medical research company’s stock valued at $1,237,000 after acquiring an additional 15,334 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “Evercore ISI Initiates Coverage on Agilent Technologies (A)” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2018/01/05/evercore-isi-initiates-coverage-on-agilent-technologies-a.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply